View details of this raise on Seedstage

Bellevue, WA

Developing bioelectromagnetic technology for non-invasive medical treatments.

• Non-Invasive Cancer Treatment: EMulate Therapeutics is developing a treatment for pediatric brain cancers using bioelectromagnetic technology.
• Pain Management Innovation: The company offers non-addictive pain relief by emulating opioid and anti-inflammatory drug signals.
• Mental Health Applications: EMulate is exploring the emulation of psychedelic compounds to manage psychiatric conditions.
• Advanced Technology Platform: The ulRFE technology records and reproduces electromagnetic patterns of drugs for therapeutic use.
• Commercial Partnerships: EMulate has licensing deals and partnerships to expand its technology’s reach globally.

EMulate Therapeutics is advancing its bioelectromagnetic technology to provide non-invasive treatments for various medical conditions. The company is working on completing FDA approval for its pediatric brain cancer treatment targeting Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG). This innovative approach uses ultra-low radio frequency energy (ulRFE) to emulate the effects of drugs like paclitaxel, offering potential therapeutic benefits without the need for physical drugs.

In addition to oncology, EMulate Therapeutics is expanding its applications to pain management and mental health. The company has demonstrated significant pain reduction using signals from opioids and anti-inflammatory compounds, providing a non-addictive alternative to traditional pain relief methods. Furthermore, EMulate is exploring the emulation of psychedelic compounds for psychiatric treatment, aiming to reduce risks associated with these drugs. With ongoing trials and commercial partnerships, EMulate Therapeutics is poised to make significant strides in transforming medical treatment through its innovative technology.

Company Info

EMulate Therapeutics develops bioelectromagnetic technology to deliver drug-like therapeutic effects without physical drugs, targeting cancer, pain, and mental health conditions.

EMulate Therapeutics is at the forefront of developing bioelectromagnetic technology to provide therapeutic benefits without the use of physical drugs. The company has created a proprietary mechanism, ulRFE technology, which records and reproduces electromagnetic patterns associated with specific compounds. These patterns are then delivered to patients through wearable devices, allowing the body to respond as if it received the actual medication, but without any chemicals entering the system. This approach aims to treat conditions such as cancer, chronic pain, and mental health disorders without the side effects typically associated with traditional drug therapies.

One of EMulate’s most advanced programs targets pediatric brain cancers, specifically Diffuse Midline Glioma, by emulating the effects of paclitaxel, a chemotherapy drug that cannot naturally cross the blood-brain barrier. Additionally, the company is exploring applications in mental health by emulating the effects of psychedelic compounds and other medications. EMulate’s technology has shown promise in veterinary studies and human trials, offering a non-invasive, non-toxic alternative to conventional treatments.